AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stegemann, M. R.
Right arrow Articles by Skogerboe, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stegemann, M. R.
Right arrow Articles by Skogerboe, T. L.
Antimicrobial Agents and Chemotherapy, July 2006, p. 2286-2292, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00077-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Antimicrobial Activity and Spectrum of Cefovecin, a New Extended- Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North America

M. R. Stegemann,1* C. A. Passmore,1 J. Sherington,1 C. J. Lindeman,2 G. Papp,2 D. J. Weigel,2 and T. L. Skogerboe2

Pfizer Animal Health, Veterinary Medicine Clinical Development, Sandwich, United Kingdom, and,1 Pfizer Animal Health, Veterinary Medicine Clinical Development, Kalamazoo, Michigan2

Received 18 January 2006/ Returned for modification 21 February 2006/ Accepted 7 March 2006

Cefovecin is a new extended-spectrum semisynthetic cephalosporin indicated for the treatment of bacterial infections in dogs and cats. This study evaluated the in vitro activity and spectrum of cefovecin against 2,641 recent clinical isolates (1,660 canine and 981 feline isolates) from Europe and the United States. MIC determinations against cefovecin and other reference antimicrobials were performed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). Cefovecin demonstrated bactericidal activity against both gram-positive and gram-negative pathogens. Cefovecin exhibited in vitro activity against all major aerobic and anaerobic bacterial pathogens associated with skin, urinary tract, and periodontal infections in dogs and cats. The MIC90 values of cefovecin against Staphylococcus intermedius, Escherichia coli, and Pasteurella multocida were 0.25 µg/ml, 1.0 µg/ml, and 0.06 µg/ml, respectively. No significant differences were observed in terms of the activities of cefovecin against pathogens from different European countries and against pathogens of European and U.S. origin.

* Corresponding author. Mailing address: Pfizer Animal Health, Veterinary Medicine Clinical Development, IPC 896, Ramsgate Rd., Sandwich CT13 9NJ, United Kingdom. Phone: 44 1304 646121. Fax: 44 1304 657158. E-mail: michael.stegemann{at}pfizer.com.

Antimicrobial Agents and Chemotherapy, July 2006, p. 2286-2292, Vol. 50, No. 7
0066-4804/06/$08.00+0     doi:10.1128/AAC.00077-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.